Volume 13 Supplement 1

Abstracts from the 26th National Congress of the Italian Society of Geriatric Surgery

Open Access

Percutaneous RF ablation versus surgical RF assisted nodulectomy in early stage HCC; our experience in elderly patients

  • Alfonso Terrone1,
  • Alberto Oldani1Email author,
  • Clemente De Rosa1,
  • Manuela Monni1 and
  • Marcello Garavoglia1
BMC Surgery201313(Suppl 1):A46

https://doi.org/10.1186/1471-2482-13-S1-A46

Published: 16 September 2013

Introduction

Surgical resection usually represents the treatment of choice for solitary hepatocellular carcinoma (HCC) in cirrhotic patients, with well preserved liver function; local ablative strategies are the best treatment option for patients with small tumors who are not candidates for surgical resection or liver transplantation [1].

The incidence of HCC increases whit age, reaching its highest prevalence among patients with more than 65 years [2].

The current literature shows a better outcome in patients with tumors smaller than 3 cm especially after percutaneous RFA [3].

Several studies showed that percutaneous radiofrequency ablation (RFA) has similar efficacy to surgical nodulectomy in the treatment of early-stage HCC, and is associated with lower complication rates and costs than resection [4].

The aim of this study is to compare the effectiveness of these treatments, in terms of morbidity, overall survival, tumor recurrence and cause of death.

Methods

Between January 2006 and January 2012 we observed 176 patients affected by HCC, 84 underwent curative treatment.

The 40 patients presenting single HCC nodes smaller than 3 cm in diameter have been treated whit radiofrequency-assisted surgical nodulectomy or with percutaneous radiofrequency.

Of these 40 patients , 23 patients were age greater than or equal to 75 years.

We divided these patients in two homogeneous groups: Group A (11 patients) treated with RF assisted surgical nodulectomy; Group B (12 patients) treated with percutaneous RFA.

The two groups result homogeneous by age, degree of liver function and tumor size.

In all cases HCC was diagnosed and staged whit classical techniques such as basic and contrast enhancement ultrasound imaging, computed tomography (CT), and magnetic resonance imaging (MRI).

All surgical procedures obtained radical resection of the tumor.

Results

Postoperative and post ablation mortality was 0.

Morbidity rates were 9.09% in Group A (1 case of peritoneal bleeding needing re operation) and 8.33% in Group B (1 case of liver abscess).

Overall mortality was 36.36% in Group A (1 patient died for end stage liver cirrhosis and 3 patients for metastatic disease 33.33% in Group B (2 patients died for local tumor recurrence and 2 patients for cardiovascular events).

No statistically significative difference were observed in terms of morbidity, overall and disease free survival between the two groups.

Conclusions

Many experience in literature show that RF and surgical resection can be used in curative treatment of HCC with good results; the less invasiveness in the main advantage of percutaneous RF application patients with compromised liver function and high stage cirrhosis: performing nodulectomy with RF-assisted liver section reduces blood loss and the need of transfusion [5].

The choice of clinical approach must be discussed between surgeons and radiologist, taking into consideration the operator’s experience and also the patient’s opinion.

Despite the relatively small number of patients observed our study confirm that RF and surgical resection can be either used in HCC treatment even in elderly patients, with no differences in terms of complication rate, overall and disease free-survival rates.

Surgical approach seems to prevent local recurrence.

Authors’ Affiliations

(1)
Department of Surgery University of Eastern Piedmont “Amedeo Avogadro, Hospital “Maggiore della Carità” Novara

References

  1. Bolondi L, Caspary W, Bennouna J, Thomson B, Van Steenbergen W, Degos F, Shan M, Moscovici M, Llovet J, Bruix J: Clinical benefit of sorafenib in hepatitis C in patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial, 2008. Presented at Gastrointestinal Cancers Symposium. 2008, Orlando, FLGoogle Scholar
  2. Parikh S, Hyman D: Hepatocellular cancer: a guide for the internist. Am J Med. 2007, 120: 194-202. 10.1016/j.amjmed.2006.11.020.View ArticlePubMedGoogle Scholar
  3. Burdio F, Mulier S, Navarro A, Figueras J, Berjano E, Poves I, Grande L: Influence of approachon outcome in radiofrequency ablation of liver tumors. Surgical Oncology. 2008, 17: 295-299. 10.1016/j.suronc.2008.03.002.View ArticlePubMedGoogle Scholar
  4. Lau WY, Lai EC: The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann. Surg. 2009, 249: 20-25. 10.1097/SLA.0b013e31818eec29.View ArticlePubMedGoogle Scholar
  5. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66 (24): 11851-11858. 10.1158/0008-5472.CAN-06-1377.View ArticlePubMedGoogle Scholar

Copyright

© Terrone et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement